On Wednesday, Israel-Headquartered Elgan Pharma Released The Findings Of Its Phase Iii Study On The Safety And Efficacy Of An Insulin Formulation For The Treatment Of Intestinal Malabsorption In Preterm Infants, Called Elgn-Gi.Premature Birth Significantly Raises The Risk Of Infant Mortality. An Estimated 15 Million Babies Are Born Preterm Each Year, And They Face A Number Of Possible Complications That Together Were Responsible For Approximately One Million Deaths Of Children Under Five Years Of Age In 2015.A Late-Stage Clinical Biopharmaceutical Company, Elgan Pharma Innovates New Solutions In Critical Neonatal Care. This Time, The Outfit Has Developed A Treatment For Feeding Intolerance In Preterm Infants Caused By Intestinal Malabsorption.The Phase Iii Study Showed That Elgn-Gi Not Only Improved Gastrointestinal (Gi) Function, But It Also Reduced Life-Threatening Complications, As Well As Time Taken To Stabilize The Infant. Usage Also Led To Shorter Hospital Stays And A Reduction In Life-Threatening Necrotizing Enterocolitis (Nec) Events. Neonatal Infants Tolerated Elgn-Gi Well And Did Not Suffer Side Effects.
